Paradigm Hits 50% Dosing in Global Knee OA Trial and Bolsters Funding

Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.

Paradigm Biopharmaceuticals reported continued momentum in its global Phase 3 trial of iPPS for knee osteoarthritis, with 50% of patients now dosed and progress toward an interim analysis expected around August 2026. The company expanded its international clinical footprint by activating a site in Hong Kong and preparing additional sites in Moldova, while maintaining a dual-CRO model to support recruitment and data quality.

The quarter also brought scientific validation through publication of a Phase 2 biomarker study in Arthritis Research & Therapy, showing favourable effects on cartilage, inflammation and pain-related biomarkers that bolster the Phase 3 rationale. Together with a published canine osteoarthritis study and new academic collaboration on bone marrow lesions, these data solidify the mechanistic case for iPPS, while a strengthened funding position of about A$45m is expected to support operations into the post-interim period.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is an Australian biopharmaceutical company focused on developing injectable pentosan polysulfate sodium (iPPS) for musculoskeletal disorders, particularly pain associated with knee osteoarthritis. The company is advancing late-stage clinical programs through a global trial network spanning Australia, the United States, Asia and emerging European sites.

YTD Price Performance: -33.82%

Average Trading Volume: 1,214,546

Technical Sentiment Signal: Sell

Current Market Cap: A$101.6M

Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.